Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
or

Arcus Biosciences Inc (RCUS)

Arcus Biosciences Inc (RCUS)
6.35 x 1 8.87 x 10
Post-market by (Cboe BZX)
8.11 +0.02 (+0.25%) 04/23/25 [NYSE]
6.35 x 1 8.87 x 10
Post-market 8.27 +0.16 (+1.97%) 17:10 ET
Quote Overview for Wed, Apr 23rd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
8.00
Day High
8.51
Open 8.21
Previous Close 8.09 8.09
Volume 3,150,964 3,150,964
Avg Vol 1,284,203 1,284,203
Stochastic %K 76.88% 76.88%
Weighted Alpha -56.32 -56.32
5-Day Change +0.10 (+1.25%) +0.10 (+1.25%)
52-Week Range 6.50 - 18.98 6.50 - 18.98
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 850,566
  • Shares Outstanding, K 105,138
  • Annual Sales, $ 258,000 K
  • Annual Income, $ -283,000 K
  • EBIT $ -330 M
  • EBITDA $ -345 M
  • 60-Month Beta 1.54
  • Price/Sales 3.14
  • Price/Cash Flow N/A
  • Price/Book 1.45

Options Overview Details

View History
  • Implied Volatility 148.51% ( +9.75%)
  • Historical Volatility 72.24%
  • IV Percentile 98%
  • IV Rank 85.54%
  • IV High 168.85% on 04/17/25
  • IV Low 28.13% on 06/20/24
  • Put/Call Vol Ratio 0.20
  • Today's Volume 127
  • Volume Avg (30-Day) 672
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 14,876
  • Open Int (30-Day) 10,306

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -1.02
  • Number of Estimates 6
  • High Estimate -0.80
  • Low Estimate -1.19
  • Prior Year -0.05
  • Growth Rate Est. (year over year) -1,940.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.50 +24.77%
on 04/07/25
Period Open: 8.94
9.19 -11.75%
on 03/24/25
-0.83 (-9.28%)
since 03/21/25
3-Month
6.50 +24.77%
on 04/07/25
Period Open: 13.33
13.80 -41.23%
on 02/05/25
-5.22 (-39.16%)
since 01/23/25
52-Week
6.50 +24.77%
on 04/07/25
Period Open: 15.50
18.98 -57.27%
on 11/11/24
-7.39 (-47.68%)
since 04/23/24

Most Recent Stories

More News
Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend

/CNW/ -- USA News Group News Commentary – Despite death rates for some cancers being on the decline, there is a global surge in cancer cases among people under...

ONCY : 0.5666 (-5.57%)
CKPT : 4.04 (unch)
RCUS : 8.11 (+0.25%)
BCTX : 5.43 (+1.50%)
ONC.TO : 0.79 (-5.95%)
AKYA : 1.2700 (+8.55%)
Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend

USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – Despite death rates for some cancers being on the decline, there is...

ONCY : 0.5666 (-5.57%)
CKPT : 4.04 (unch)
RCUS : 8.11 (+0.25%)
BCTX : 5.43 (+1.50%)
AKYA : 1.2700 (+8.55%)
ONC.TO : 0.79 (-5.95%)
S&P Futures Tick Lower Ahead of FOMC Meeting, Microsoft and Alphabet Earnings on Tap

March S&P 500 E-Mini futures (ESH24) are trending down -0.15% this morning as investors looked ahead to the first Federal Reserve monetary policy committee meeting of the year and quarterly reports from...

WHR : 77.74 (+0.54%)
META : 520.27 (+4.00%)
GOOGL : 155.35 (+2.56%)
SMCI : 32.90 (+7.59%)
RCUS : 8.11 (+0.25%)
ADM : 48.12 (-0.87%)
FFIV : 262.46 (+3.02%)
PFE : 22.39 (-0.62%)
ESH24 : 5,101.67s (-1.01%)
MSFT : 374.39 (+2.06%)
SBUX : 82.81 (+1.30%)
CALX : 36.92 (-1.83%)
From laggards to leaders: Small caps on the rise

Despite large-cap dominance, signs suggest a shift to small-cap leadership. Valuations, positive Q3 results, and historical patterns point to potential gains.

NVDA : 102.71 (+3.86%)
META : 520.27 (+4.00%)
MDY : 509.03 (+1.28%)
RCUS : 8.11 (+0.25%)
XLC : 91.93 (+1.60%)
SPSM : 38.18 (+1.22%)
TSLA : 250.74 (+5.37%)
PHM : 101.06 (+0.17%)
XLK : 198.04 (+2.90%)
RCL : 207.50 (+3.92%)
CDMO : 12.49 (+0.08%)
SPY : 535.42 (+1.55%)
MarketBeat Week in Review – 7/10 - 7/14

As inflation moderates, Investors are optimistic for the second quarter earnings season and that optimism is evident in some of the top stories from this week

ENPH : 45.07 (-15.65%)
BTU : 12.12 (-2.42%)
AVGO : 176.91 (+4.32%)
RIVN : 11.80 (+3.87%)
PFE : 22.39 (-0.62%)
ARKK : 47.95 (+3.97%)
DPZ : 485.88 (-0.05%)
BYND : 2.59 (-0.96%)
TSLA : 250.74 (+5.37%)
NKLA : 0.1830 (-28.74%)
CAVA : 86.45 (+6.33%)
CMG : 48.76 (+3.52%)
Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus

Regulatory filings show Gilead Sciences' purchase of shares in AlloVir and Arcus. Strategic investments in the biotech sector are fairly common to boost growth.

VIGL : 1.8100 (+0.56%)
FLACU : 9.50 (+2.48%)
BGNE : 184.71 (+0.49%)
JSPR : 4.56 (+4.35%)
ALVR : 9.81 (+1.55%)
RCUS : 8.11 (+0.25%)
NVS : 110.13 (-1.15%)
GILD : 106.38 (+0.82%)
AMGN : 277.90 (-0.18%)
BMY : 48.53 (-2.59%)
3 Biotech Stocks to Buy for Long-Term Gains

The biotech sector is one of the most volatile sectors, but here are three biotech stocks that offer opportunities for patient biotech stock investors.

CRSP : 38.54 (-1.76%)
VRTX : 492.42 (+0.40%)
RCUS : 8.11 (+0.25%)
GILD : 106.38 (+0.82%)
REGN : 587.85 (+0.40%)
CRBU : 0.8423 (+0.79%)
XBI : 79.10 (+1.88%)
PFE : 22.39 (-0.62%)
NTLA : 8.09 (-2.65%)
Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced...

RCUS : 8.11 (+0.25%)
Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced...

RCUS : 8.11 (+0.25%)
Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced...

RCUS : 8.11 (+0.25%)

Business Summary

Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in...

See More

Key Turning Points

3rd Resistance Point 8.92
2nd Resistance Point 8.72
1st Resistance Point 8.41
Last Price 8.11
1st Support Level 7.90
2nd Support Level 7.70
3rd Support Level 7.39

See More

52-Week High 18.98
Fibonacci 61.8% 14.21
Fibonacci 50% 12.74
Fibonacci 38.2% 11.27
Last Price 8.11
52-Week Low 6.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective